Rohan Halder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rohan Halder has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Narendra Agrawal
Department of Haematology & BMT Unit, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, Delhi 110085, India
12 shared publicationsDinesh Bhurani
Department of Haematology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre
9 shared publications- Dinesh Bhurani
Rajiv Gandhi Cancer Institute & Research Centre
8 shared publications - Reema Singh
Department of Haematology & BMT Unit, Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini, Delhi 110085, India; School of Pharmacy, Lingaya's Vidyapeeth, Faridabad, Haryana 121002, India
8 shared publications Reema Singh
Department of Haematology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre
7 shared publicationsTribikram Panda
Department of Haematology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre
7 shared publications
Latest Publications
- 7 April 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (3) , 221-228
“Assessing Long-Term Health-Related Quality of Life in Children with β-Thalassemia Major Following Hematopoietic Stem Cell Transplantation” – A Cross-Sectional Comparative Study
India faces a major challenge with thalassemia major (β-TM), a serious genetic blood disorder affecting many people. About 150,000 children currently live with this condition, with another 10,000–1...
- 7 April 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (3) , 221-228
“Assessing Long-Term Health-Related Quality of Life in Children with β-Thalassemia Major Following Hematopoietic Stem Cell Transplantation” – A Cross-Sectional Comparative Study
India faces a major challenge with thalassemia major (β-TM), a serious genetic blood disorder affecting many people. About 150,000 children currently live with this condition, with another 10,000–1...
- 28 March 2026
- Published by Elsevier in Leukemia Research
- Vol. 165, 108218
Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study
- 28 March 2026
- Published by Elsevier in Leukemia Research
- Vol. 165, 108218
Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study
- 2 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 132-140
Matched Unrelated Donor (MUD) Transplants Show Promising Outcomes in Thalassemia Patients Aged ≤ 12 Years
- 2 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 132-140
Matched Unrelated Donor (MUD) Transplants Show Promising Outcomes in Thalassemia Patients Aged ≤ 12 Years
- Open Access
- 15 April 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (4) , 2483-2493
Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India
Chronic myeloid leukemia in the blast phase (BP-CML) remains challenging despite advancements in tyrosine kinase inhibitors (TKIs). This study retrospectively assessed BP-CML patients who underwent allogeneic stem cell transplantation (allo-SCT) from June 2009 to December 2022. Thirty-three patients were included and the median age was 41 years, with a predominantly male cohort. Myeloablative conditioning and peripheral blood stem cells were used in the majority of the patients. The estimated 2-year overall survival (OS) was 48.3% of the cohort. Relapse occurred in 48.5% of patients, typically within 3 months post-transplant. Post-transplant TKI maintenance showed a significant association with improved OS (p-value = 0.001). The study highlights the need for early intervention and optimized post-transplant maintenance to improve outcomes.
- 15 April 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (4) , 2483-2493
Open AccessAllogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India
Chronic myeloid leukemia in the blast phase (BP-CML) remains challenging despite advancements in tyrosine kinase inhibitors (TKIs). This study retrospectively assessed BP-CML patients who underwent allogeneic stem cell transplantation (allo-SCT) from June 2009 to December 2022. Thirty-three patients were included and the median age was 41 years, with a predominantly male cohort. Myeloablative conditioning and peripheral blood stem cells were used in the majority of the patients. The estimated 2-year overall survival (OS) was 48.3% of the cohort. Relapse occurred in 48.5% of patients, typically within 3 months post-transplant. Post-transplant TKI maintenance showed a significant association with improved OS (p-value = 0.001). The study highlights the need for early intervention and optimized post-transplant maintenance to improve outcomes.
- 4 March 2025
- Published by Taylor & Francis in Hemoglobin
- Vol. 49 (2) , 78-84
Evaluating Health-Related Quality of Life in Thalassemia: Low-Dose Thalidomide vs. Standard Care—Insights from a Comparative Study
Thalassemia is a hemoglobinopathy that affects many people worldwide. Although treatments such as iron chelation and safe transfusions have improved life expectancy, patients still experience complications. Thalidomide, with its immunomodulatory and anti-angiogenic properties, has been found to increase the expression of the γ-globin gene and promote erythroid cell proliferation. Our study compared thalidomide-treated and standard therapy groups, assessing health-related quality of life in thalassemia patients using the SF-36 questionnaire tailored for the Indian population. A total of 84 patients (Thalidomide: 50, Standard: 34) were enrolled. Sixty-four percent of patients on thalidomide became transfusion-free within 4-6 months. The mean duration of transfusion requirement in the thalidomide group increased from 20 to 35 days in 30% of patients. Patients aged ≤ 20 years, without splenectomy, and unemployed had significantly better physical health component (PHC) scores with thalidomide therapy compared to standard therapy (P = 0.027, P = 0.0007, and P = 0.045, respectively). On the other hand, patients aged >20 years and with intact spleen had significantly better mental health component (MHC) scores with thalidomide therapy compared to standard therapy (P = 0.006 and P < 0.00001, respectively). Thalidomide therapy showed significantly better MHC scores than standard therapy on all four scales. Thalidomide therapy shows significant promise in improving the HRQoL for thalassemia patients, particularly in those with early initiation, as indicated by enhanced physical and mental health component scores and improved vitality, emotional well-being, role-emotional, and social functioning compared to standard care.
- 4 March 2025
- Published by Taylor & Francis in Hemoglobin
- Vol. 49 (2) , 78-84
Evaluating Health-Related Quality of Life in Thalassemia: Low-Dose Thalidomide vs. Standard Care—Insights from a Comparative Study
Thalassemia is a hemoglobinopathy that affects many people worldwide. Although treatments such as iron chelation and safe transfusions have improved life expectancy, patients still experience complications. Thalidomide, with its immunomodulatory and anti-angiogenic properties, has been found to increase the expression of the γ-globin gene and promote erythroid cell proliferation. Our study compared thalidomide-treated and standard therapy groups, assessing health-related quality of life in thalassemia patients using the SF-36 questionnaire tailored for the Indian population. A total of 84 patients (Thalidomide: 50, Standard: 34) were enrolled. Sixty-four percent of patients on thalidomide became transfusion-free within 4-6 months. The mean duration of transfusion requirement in the thalidomide group increased from 20 to 35 days in 30% of patients. Patients aged ≤ 20 years, without splenectomy, and unemployed had significantly better physical health component (PHC) scores with thalidomide therapy compared to standard therapy (P = 0.027, P = 0.0007, and P = 0.045, respectively). On the other hand, patients aged >20 years and with intact spleen had significantly better mental health component (MHC) scores with thalidomide therapy compared to standard therapy (P = 0.006 and P < 0.00001, respectively). Thalidomide therapy showed significantly better MHC scores than standard therapy on all four scales. Thalidomide therapy shows significant promise in improving the HRQoL for thalassemia patients, particularly in those with early initiation, as indicated by enhanced physical and mental health component scores and improved vitality, emotional well-being, role-emotional, and social functioning compared to standard care.
- Open Access
- 13 June 2024
- Published by Elsevier in Leukemia Research Reports
- Vol. 21, 100466
A tertiary care centre experience with Elranatamab: A report of three cases
- 13 June 2024
- Published by Elsevier in Leukemia Research Reports
- Vol. 21, 100466
Open AccessA tertiary care centre experience with Elranatamab: A report of three cases
- 3 May 2024
- Published by Taylor & Francis in Hemoglobin
- Vol. 48 (3) , 186-191
ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience
Graft rejection and Graft-versus-host disease (GVHD) are some of the significant factors resulting in morbidity and mortality following allogeneic hematopoietic cell transplantation. Prophylaxis for GVHD using T-cell depleting agents is helpful in reducing the transplant-related mortality and graft rejection. Both tATG and fATG exhibit varied amounts of antibody specificities and perform distinct immunomodulatory effects, regardless of their capacity to deplete T-lymphocytes. We conducted this single-center, retrospective study at our center to compare both formulations. Twenty-six patients were included in the study, 13 in each cohort. The median age at diagnosis of β-thalassemia was 5 months (range, 3-12 months) in the tATG group and 6 months (range, 3-9 months) in the f-ATG group, respectively. Acute GVHD was observed in 1 (7.7) and 2(15.4) in the tATG and fATG group, respectively. No cases of chronic GVHD were observed in either group. There was no difference in the mixed chimerism observed at 6 months in both groups, tATG (n = 5, 38.5%) and fATG (n = 6, 46.15). There was 1 (7.6) rejection at day +72 observed in the tATG group, whereas no rejection was observed in the fATG group. At a mean follow-up duration of 288 days since transplant, there were no deaths in either of the groups. In conclusion, both ATG preparations showed equivalent effectiveness in preventing rejections and GVHD. However, further larger studies are required to establish the long-term efficacy and safety of both formulations in ASCT.
- 3 May 2024
- Published by Taylor & Francis in Hemoglobin
- Vol. 48 (3) , 186-191
ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience
Graft rejection and Graft-versus-host disease (GVHD) are some of the significant factors resulting in morbidity and mortality following allogeneic hematopoietic cell transplantation. Prophylaxis for GVHD using T-cell depleting agents is helpful in reducing the transplant-related mortality and graft rejection. Both tATG and fATG exhibit varied amounts of antibody specificities and perform distinct immunomodulatory effects, regardless of their capacity to deplete T-lymphocytes. We conducted this single-center, retrospective study at our center to compare both formulations. Twenty-six patients were included in the study, 13 in each cohort. The median age at diagnosis of β-thalassemia was 5 months (range, 3-12 months) in the tATG group and 6 months (range, 3-9 months) in the f-ATG group, respectively. Acute GVHD was observed in 1 (7.7) and 2(15.4) in the tATG and fATG group, respectively. No cases of chronic GVHD were observed in either group. There was no difference in the mixed chimerism observed at 6 months in both groups, tATG (n = 5, 38.5%) and fATG (n = 6, 46.15). There was 1 (7.6) rejection at day +72 observed in the tATG group, whereas no rejection was observed in the fATG group. At a mean follow-up duration of 288 days since transplant, there were no deaths in either of the groups. In conclusion, both ATG preparations showed equivalent effectiveness in preventing rejections and GVHD. However, further larger studies are required to establish the long-term efficacy and safety of both formulations in ASCT.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 5842
A Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India
Disclosures. No relevant conflicts of interest to declare.Figure 1
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 5842
Open AccessA Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India
Disclosures. No relevant conflicts of interest to declare.Figure 1
- 23 September 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (1) , 347-349
Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin’s lymphoma and primary mediastinal B cell lymphoma
- 23 September 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (1) , 347-349
Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin’s lymphoma and primary mediastinal B cell lymphoma